Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998696 | 1.00 | MAOA (0.50) | MAOAOPRM1OPRK1OPRL1CHRNB4 | |
| SCHEMBL5999673 | 0.96 | MAOA (0.52) | MAOAOPRM1OPRK1OPRL1F10 | |
| SCHEMBL5998591 | 0.88 | MAOA (0.38) | MAOAOPRM1OPRK1OPRL1CHRNB4 | |
| SCHEMBL5999433 | 0.88 | MAOA (0.38) | MAOAOPRM1OPRK1OPRL1CHRNB4 | |
| SCHEMBL5999423 | 0.88 | MAOA (0.38) | MAOAOPRM1OPRK1OPRL1CHRNB4 | |
| SCHEMBL5503079 | 0.83 | MAOA (0.39) | MAOAF10MAOB | |
| SCHEMBL5998076 | 0.83 | MAOA (0.39) | MAOAOPRM1OPRK1OPRL1F10 | |
| SCHEMBL5998601 | 0.82 | MAOA (0.51) | MAOAF10MAOB | |
| SCHEMBL5515420 | 0.81 | MAOA (0.38) | MAOAOPRM1OPRK1OPRL1F10 | |
| SCHEMBL5501276 | 0.79 | MAOA (0.48) | MAOAF10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | claimed |
| EP-1781642-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006016221-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | MAOA 766/4885OPRM1 166/4885OPRK1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.